2023
Sex effects in predictors of smoking abstinence and neuropsychiatric adverse events in the EAGLES trial
McKee S, Lawrence D, Saccone P, McRae T, Anthenelli R. Sex effects in predictors of smoking abstinence and neuropsychiatric adverse events in the EAGLES trial. Drug And Alcohol Dependence Reports 2023, 8: 100177. PMID: 37520849, PMCID: PMC10372180, DOI: 10.1016/j.dadr.2023.100177.Peer-Reviewed Original ResearchNeuropsychiatric adverse eventsCessation outcomesContinuous abstinenceAdverse eventsPsychiatric cohortPsychiatric statusLower oddsEfficacy of vareniclineSmoking cessation medicationsPoint prevalence abstinenceHigher baseline levelsSex effectsLogistic regression modelsEAGLES trialCessation medicationsBaseline characteristicsSmoking historyMedication useNicotine patchPoint prevalenceStudy treatmentBaseline variablesBaseline cigarettesAbstinence outcomesSignificant interaction
2010
Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion
Mazure CM, Toll B, McKee SA, Wu R, O’Malley S. Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion. Drug And Alcohol Dependence 2010, 114: 68-72. PMID: 20832955, PMCID: PMC3016455, DOI: 10.1016/j.drugalcdep.2010.07.024.Peer-Reviewed Original ResearchConceptsMenstrual cycle phaseQuit datePoint prevalence abstinencePremenopausal womenBupropion SRFollicular phaseLuteal phaseAbsence of pharmacotherapySustained release bupropionOpen-label trialCycle phaseMechanism of actionRelease bupropionLabel trialNicotine replacementCessation interventionsOpen trialTreatment completionCessation outcomesContinuous abstinenceQuit dayGonadal hormonesTreatment periodAbstinence outcomesQuit attemptsChanges in smoking expectancies in abstinent, reducing, and non-abstinent participants during a pharmacological trial for smoking cessation
Weinberger AH, McKee SA, George TP. Changes in smoking expectancies in abstinent, reducing, and non-abstinent participants during a pharmacological trial for smoking cessation. Nicotine & Tobacco Research 2010, 12: 937-943. PMID: 20644207, PMCID: PMC2928936, DOI: 10.1093/ntr/ntq120.Peer-Reviewed Original ResearchConceptsNegative affect reductionNegative physical feelingsWeight control beliefsNon-abstinent participantsSmoking status interactionSmoking expectanciesNegative affectSmoking cessation treatmentControl beliefsSmoking beliefsSmoking cessation trialPoint prevalence abstinenceSocial facilitationBaseline expectanciesEnd of treatmentSocial interactionSmoking treatmentCessation outcomesQuit attemptsAbstinence outcomesCessation treatmentPhysical feelingsGender differencesCessation trialBeliefs
2008
Developing human laboratory models of smoking lapse behavior for medication screening
McKee SA. Developing human laboratory models of smoking lapse behavior for medication screening. Addiction Biology 2008, 14: 99-107. PMID: 18855800, PMCID: PMC2732001, DOI: 10.1111/j.1369-1600.2008.00135.x.Peer-Reviewed Original ResearchConceptsMedication screeningHuman laboratory modelSmoking behaviorMedication developmentSubsequent ad libitum smokingAd libitum smokingDrug Administration approvalSelf-administration sessionsMedication signalsCessation medicationsLapse behaviorAdministration approvalFirst cigaretteAbstinence outcomesQuit attemptsSmoking relapseUS FoodSmokingSmokersRelapseImportant targetTranslational workCigarettesScreeningMechanistic evaluation